A Phase 3, Multicenter, Randomized, Double-Blind, Active Comparator-Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX 23 Eight Weeks Later in Adults Infected With HIV (PNEU-WAY)
Status: Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 11 Oct 2019
Price : $35 *
At a glance
- Drugs V 114 (Primary) ; Pneumococcal 13-valent CRM197 vaccine conjugate; Pneumococcal vaccine
- Indications Pneumococcal infections
- Focus Adverse reactions; Pharmacodynamics; Registrational
- Acronyms PNEU-WAY
- Sponsors Merck Sharp & Dohme
- 04 Oct 2019 Planned End Date changed from 31 Jan 2020 to 20 Jan 2020.
- 04 Oct 2019 Planned primary completion date changed from 31 Jan 2020 to 20 Jan 2020.
- 24 Sep 2019 Planned End Date changed from 10 Feb 2020 to 31 Jan 2020.